Vor Biopharma (NASDAQ:VOR) Upgraded to Strong-Buy at Citigroup

Key Points

• Citigroup upgraded Vor Biopharma to “strong buy,” while the broader analyst consensus remains “Moderate Buy” with a $38.00 average price target.
• VOR shares traded at $18.03, down $1.31, with a 52-week range of $6.50 to $31.31. The company also reported a quarterly loss of $0.80 per share, missing estimates by $0.11.
• Institutional investors and hedge funds own 97.29% of Vor Biopharma, with several major firms recently increasing or initiating positions.

Vor Biopharma (NASDAQ:VOR - Get Free Report) was upgraded by Citigroup to a "strong-buy" rating in a research report issued on Thursday, Zacks reports.

Several other equities research analysts also recently weighed in on VOR. Wedbush increased their price target on Vor Biopharma from $18.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, August 12th. Wall Street Zen upgraded shares of Vor Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised Vor Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, September 14th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, Vor Biopharma has a consensus rating of "Moderate Buy" and a consensus target price of $38.00.

Vor Biopharma Price Performance

NASDAQ VOR traded down $1.31 during trading hours on Thursday, hitting $18.03. 733,078 shares of the company were exchanged, compared to its average volume of 1,316,671. The company has a 50 day moving average of $21.57 and a two-hundred day moving average of $18.37. Vor Biopharma has a 52-week low of $6.50 and a 52-week high of $31.31.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). Analysts forecast that Vor Biopharma will post -2.56 EPS for the current fiscal year.

Institutional Trading of Vor Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of VOR. Braidwell LP grew its position in Vor Biopharma by 22.8% in the 2nd quarter. Braidwell LP now owns 573,104 shares of the company's stock worth $10,551,000 after purchasing an additional 106,330 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Vor Biopharma in the first quarter worth approximately $2,298,000. Bank of America Corp DE lifted its holdings in shares of Vor Biopharma by 28,408.1% during the first quarter. Bank of America Corp DE now owns 112,892 shares of the company's stock valued at $2,014,000 after purchasing an additional 112,496 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Vor Biopharma in the second quarter worth approximately $1,799,000. Finally, Simplify Asset Management Inc. acquired a new stake in Vor Biopharma during the 1st quarter valued at $955,000. 97.29% of the stock is owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company's approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor's technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.